Please assess the completion status of the following clinical trial:

Trial Title: Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed.~* Male and female subjects age 18-78 years, inclusive, with controlled health condition as determined by past medical history, physical examination, electrocardiogram and laboratory test at screening.~* patients with Type 2 diabetes, HbA1c \<10% at screening.~* Body mass index (BMI) ≤ 50 kg/m\^2 at screening.~Exclusion Criteria:~* Patients with Type 1 diabetes~* Evidence of clinically significant liver function test: ALT, AST, gamma-GT, alkaline phosphatase \>3 X ULN; serum bilirubin \> 1.5 X ULN.~* Patients undergoing any method of dialysis~* clinically significant GI disorder related to malabsorption or that may affect drug or glucose absorption.~* subjects who experienced ketoacidosis, lactic acidosis or hyperosmolar coma within 6 months of screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Mild (Type: EXPERIMENTAL): Patients with mild renal impairment (Group 1) received LIK066 50 mg qd before breakfast for 7 days.
- Moderate A (Type: EXPERIMENTAL): Patients with moderate renal impairment grade A (Group 2) received LIK066 50 mg qd before breakfast for 7 days.
- Moderate B (Type: EXPERIMENTAL): Patients with moderate renal impairment grade B (Group 3) received LIK066 50 mg qd before breakfast for 7 days.
- Severe (Type: EXPERIMENTAL): Patients with severe renal impairment (Group 4) received LIK066 50 mg qd before breakfast for 7 days.
- Normal (Type: EXPERIMENTAL): Patients with normal renal function (Group 5) received LIK066 50 mg qd before breakfast for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).